PBM
KYMR icon

Propel Bio Management’s Kymera Therapeutics KYMR Stock Holding History

Propel Bio Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,359
Closed -$2.27M – 23
2024
Q4 		$2.27M Hold
56,359
– – 2.25% 12
2024
Q3 		$2.67M Hold
56,359
– – 1.55% 12
2024
Q2 		$1.68M Hold
56,359
– – 1.09% 18
2024
Q1 		$2.27M Hold
56,359
– – 1.32% 15
2023
Q4 		$1.43M Buy
+56,359
New +$1.01M 1.19% 22

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Propel Bio Management's KYMR Position: Q1 2025 in Review

Propel Bio Management sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 56,359 shares — an estimated $2.27M sold.

Propel Bio Management first reported a position in KYMR in Q4 2023 and held it in 5 quarters. The position peaked at $2.67M in Q3 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • Propel Bio Management reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Propel Bio Management sold 56,359 Kymera Therapeutics shares in Q1 2025, an estimated $2.27M.
  • Propel Bio Management first reported a position in Kymera Therapeutics in Q4 2023 and held it in 5 quarters.
  • Propel Bio Management's Kymera Therapeutics position peaked at $2.67M in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on Propel Bio Management's 13F filing for Q1 2025, filed 15 May 2025.